黑料吃瓜不打烊

You are now in the main content area
Abdelwahab Omri

Abdelwahab Omri

Full Professor, School of Natural Sciences
School of Natural Sciences
Science, Engineering and Architecture
S-416, Science Building
705.675.1151 ext +1 (705) 6751151 ext 2190 aomri@laurentian.ca

Biography

Dr Omri is currently a Full Professor in the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology,?the Biomolecular?Sciences PhD Programme, School of Rural and Northern Health PhD. He has been active in the vaccine and drug delivery field for over 20 years, and has made important contributions to the development of liposomes and nanomedicines for anti-infective drugs. He has over 150 peer-reviewed publications and is an inventor on 3 patents. He is frequently an invited speaker at national and international conferences. In addition to research, Dr. Omri is actively involved in the research training of both undergraduate and graduate students. Dr. Omri has served in administrative capacities in several national and international scientific societies. He has served on a number of Editorial Boards and Granting Agencies in Canada and abroad.?He was an?Academic?Colleague?to the Council of Ontario Universities for 2?terms.

Education

  • Pharm B
  • MSc
  • PhD

On The Web

http://omripharm.webs.com/
Download vCard aomri@laurentian.ca 705.675.1151 ext +1 (705) 6751151 ext 2190 Abdelwahab Omri

Research

Lipid-based drug and vaccine delivery systems

?Liposomes are one of the most versatile biochemical tools. They are microscopic, spherical closed vesicles composed of one or more lipid bilayer that form when phospholipids are hydrated. Hydrophilic molecules can be incorporated into the aqueous compartment and lipophilic molecules can be encapsulated in the lipid bilayers. Liposomes by themselves are considered nonimmunogenic, biodegradable and nontoxic. They have been utilized in numerous biomedical applications including gene therapy, for delivery of drugs and vaccines, cancer imaging agents and cosmetics. Liposomes have the capability to incorporate selected bioactive biologicals and adjuvant molecules and potentiate their efficacy and minimize their toxicity. They do this by beneficially altering the biodistribution and pharmacokinetics of the molecule in the body following its administra-tion through various routes of delivery.

My research program is centered on the design, formulation, development and characterization of drug and vaccine delivery systems; particularly those based on liposomes. A special focus on the site-specific targeting, controlled release, drug resistance, pharmacokinetic, pharmacodynamic, metabolism and toxicity of free and liposome-encapsulated biological active agents.

Research Interests

1. Liposomal delivery of antisense oligonucleotides. Effect on P-glycoprotein function in multidrug resistant cells in vitro and in vivo studies. Cationic liposome formulations are used to promote the penetration of antisense oligonucleotides into the cell membrane and protect them from enzymatic degradation (nucleases).

2. Liposomal delivery of antimicrobial agents towards resistant bacterial pathogens: pulmonary and systemic infections. Construction of liposomes with high encapsulation efficiency, favorable antimicrobial release profile and enhanced bactericidal activity, to overcome the problem of bacterial resistance caused by low permeability of the bacterial cell envelope and by production of antimicrobial-inactivating enzymes.

3. Liposomal formulations of drugs and vaccine for oral delivery. Liposomes are used to protect the encapsulated agents from the harsh gastrointestinal milieu (low pH, phospholipases, and bile salts) and to enhance their absorption to the systemic circulation and to increase the efficacy of these agents while minimizing their frequency of administration. Special liposomal formulation will be prepared, characterized and assayed for their efficacy in vitro and in animal models.

Awards

  • Journal of Experimental Pharmacology?(Editor in Chief)-(Springer)
  • Scientific Reports?(Nature)
  • BMC Pharmacology and Toxicology
  • PLOS ONE
  • Discovery Medicine
  • Discover Medicine (Springer)
  • Exploration in Immunology
  • Recent Advances in Drug Delivery and Formulation
  • Expert Opinion on Drug Delivery
  • Expert Review of Anti-infective Therapy
  • Drug Delivery
  • BioMed Research International
  • Antibiotics?(MDPI)
  • Molecules?(MDPI)
  • Pharmaceuticals?(MDPI)
  • Materials?(MDPI)
  • Drugs and Drug Candidates?(MDPI)
  • International Journal of Microbiology (Wiley)
  • Journal of Nanomaterials
  • European Journal of Chemistry
  • The Natural Products Journal
  • Journal of Pharmaceutical Technology Drug Research
  • Oriental Journal of Chemistry
  • Drug Delivery Letters
  • Biocell

Teaching

  • ?CHMI 3226 FL? Biochimie II – Biochimie métabolique
  • CHMI 3226 EL? Biochemistry II – Metabolic Biochemistry
  • CHMI 3217 FL Biochimie des acides nucléiques
  • CHMI 3257 EL Principles of? Pharmcology?
  • CHMI 4287/5287 EL Biochemical Toxicology
  • CHMI-4446 EL Drug Design and Development
  • BIOL 2026 EL Introduction to Microbiologyy
  • CHMI 4236 FL Biotechnologie pharmaceutique
  • Novel Drug delivery System (NDDS)?

?

Courses taught:

  • CHMI 2227 EL Biochemistry I- Structural Biochemistry
  • CHMI 2227 FL Biochimie I- Biochimie structurale
  • CHMI 3217 EL Biochemistry of Nucleic Acids
  • CHMI 3217 FL Biochimie des acides nucléiques
  • CHMI 3226 FL? Biochimie II – Biochimie métabolique
  • CHMI 3226 EL? Biochemistry II – Metabolic Biochemistry
  • CHMI 3257 EL Principles of? Pharmcology?
  • CHMI 4216 EL Advanced Biochemistry (Molecular biology)
  • CHMI 4216 FL Biochmie avancée (Biologie moléculaire)
  • CHMI 4236 FL Biotechnologie pharmaceutique
  • CHMI 4287/5287 EL Biochemical Toxicology
  • CHMI 4297 EL Biochemistry-immune system?
  • CHMI 4615 EL Seminars (4th year thesis coordinator)
  • CHMI 4615 FL Seminars (4th year thesis coordinator)-
  • CHMI 5606 EL Seminars (Master coordinator)
  • CHMI 5606 FL Seminars (Master coordinator)
  • BMOL 6106 EL Adv. Topics in Cell Regulation (PhD. course coordinator)
  • MIDW 2406 EL Pharmacotherapy
  • SFEM 2406 FL Pharmacologie & Thérapeutique?

?

?

Publications

  1. Khot S, Krishnaveni A, Gharat S, Momin M, Bhavsar C, Omri A. Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment. Expert Opin Drug Deliv. 2024 Nov 15. doi: 10.1080/17425247.2024.2429702. Epub ahead of print. PMID: 39545622.
  2. Debnath SK, Debnath M, Ghosh A, Srivastava R, Omri A. Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications. Pharmaceuticals (Basel). 2024 Oct 18;17(10):1389. doi: 10.3390/ph17101389. PMID: 39459028; PMCID: PMC11510357.
  3. Deshpande A, Likhar R, Khan T, Omri A. Decoding drug resistance in?Mycobacterium tuberculosis?complex: genetic insights and future challenges. Expert Rev Anti Infect Ther. 2024 Jul;22(7):511-527. doi: 10.1080/14787210.2024.2400536. Epub 2024 Sep 4. PMID: 39219506.
  4. Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M. Advances in artificial intelligence for drug delivery and development: A comprehensive review. Comput Biol Med. 2024 Aug;178:108702. doi: 10.1016/j.compbiomed.2024.108702. Epub 2024 Jun 7. PMID: 38878397.
  5. Suvarna V, Mallya R, Deshmukh K, Sawant B, Khan TA, Omri A. Novel Vesicular Bilosomal Delivery Systems for Dermal/Transdermal Applications. Curr Drug Deliv. 2024;21(7):961-977. doi: 10.2174/1567201820666230707161206. PMID: 37424346.
  6. Hariharan K, Mehta T, Shah J, Dave H, Sami A, Omri A. Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma. Int J Pharm. 2023 Jul 25;642:123144. doi: 10.1016/j.ijpharm.2023.123144. Epub 2023 Jun 16. PMID: 37330155.
  7. Mahami S, Salehi M, Mehrabi M, Vahedi H, Hassani MS, Bitaraf FS, Omri A. pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis. Int J Biol Macromol. 2023 Jul 31;244:125332. doi: 10.1016/j.ijbiomac.2023.125332. Epub 2023 Jun 10. PMID: 37302632.
  8. Parab A, Kumar Bhatt L, Omri A. Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy.?Biomedicines. 2023; 11(1):169.
  9. Mehta, Kunal, Mihir Khambete, Arundhati Abhyankar, and Abdelwahab Omri. 2023. "Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents"?Pharmaceuticals?16, no. 3: 377. ?
  10. Nadar S, Khan T, Omri A. Expert Rev Anti Infect Ther. 2022 Nov;20(11):1425-1433. doi: 10.1080/14787210.2022.2128763. Epub 2022 Sep 30.
  11. Singh P, Waghambare P, Khan TA, Omri A. Expert Opin Drug Deliv. 2022 Jun;19(6):653-670. doi: 10.1080/17425247.2022.2084531. Epub 2022 Jun 13.
  12. Debnath SK, Debnath M, Srivastava R, Omri A. Expert Rev Anti Infect Ther. 2022 Sep;20(9):1187-1204. doi: 10.1080/14787210.2022.2082944. Epub 2022 Jun 6.
  13. Muddineti OS, Omri A. Expert Opin Drug Deliv. 2022 May;19(5):559-576. doi: 10.1080/17425247.2022.2075845. Epub 2022 May 22.
  14. Hossain Z, Reza AHMM, Qasem WA, Friel JK, Omri A. Pediatr Res. 2022 Oct;92(4):951-955. doi: 10.1038/s41390-022-01940-0. Epub 2022 Jan 18.
  15. Gbian DL, Omri A. Lipid-Based Drug Delivery Systems for Diseases Managements.?Biomedicines. 2022; 10(9):2137.
  16. Suvarna V, Nair A, Mallya R, Khan T, Omri A. Antimicrobial Nanomaterials for Food Packaging.?Antibiotics. 2022; 11(6):729.
  17. Jethva P, Momin M, Khan T, Omri A. Lanthanide-Doped Upconversion Luminescent Nanoparticles—Evolving Role in Bioimaging, Biosensing, and Drug Delivery.?Materials. 2022; 15(7):2374.
  18. Nadar S, Khan T, Patching SG, Omri A. Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance.?Microorganisms. 2022; 10(2):303.
  19. Nair A, Mallya R, Suvarna V, Khan TA, Momin M, Omri A. Nanoparticles—Attractive Carriers of Antimicrobial Essential Oils.?Antibiotics. 2022; 11(1):108.
  20. Jahan H, Tumpa IJ, Qasem WA, Moniruzzaman M, Pervin MA, Akter R, Omri A, Min T, Hossain Z. Front Nutr. 2021 Nov 1;8:733402. doi: 10.3389/fnut.2021.733402. eCollection 2021.
  21. Hossain Z, Hossain MS, Ema NS, Omri A. Heliyon. 2021 Oct 28;7(11):e08285. doi: 10.1016/j.heliyon.2021.e08285. eCollection 2021 Nov.
  22. Momin M, Mishra V, Gharat S, Omri A. Expert Opin Drug Deliv. 2021 Nov;18(11):1741-1760. doi: 10.1080/17425247.2021.1989407. Epub 2021 Oct 12.
  23. Debnath SK, Debnath M, Srivastava R, Omri A. Expert Opin Drug Deliv. 2021 Nov;18(11):1659-1672. doi: 10.1080/17425247.2021.1981287. Epub 2021 Sep 21.
  24. ?Hossain Z, Qasem WA, Friel JK, Omri A. Nutrients. 2021 Aug 11;13(8):2755. doi: 10.3390/nu13082755.
  25. Debnath SK, Srivastava R, Debnath M, Omri A. Expert Rev Respir Med. 2021 Oct;15(10):1251-1270. doi: 10.1080/17476348.2021.1919514. Epub 2021 May 4.
  26. Gbian DL, Omri A. Expert Opin Drug Deliv. 2021 May;18(5):535-552. doi: 10.1080/17425247.2021.1874343. Epub 2021 Jan 22.
  27. Gupta B, Mishra V, Gharat S, Momin M, Omri A. Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems.?Pharmaceuticals. 2021; 14(11):1201.
  28. Hossain Z, Qasem WA, Friel JK, Omri A. Effects of Total Enteral Nutrition on Early Growth, Immunity, and Neuronal Development of Preterm Infants.?Nutrients. 2021; 13(8):2755.
  29. ?Chauhan A, Khan T, Omri A. Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy.?International Journal of Molecular Sciences. 2021; 22(15):8037.
  30. Shringarpure M, Gharat S, Momin M, Omri A. Expert Opin Drug Deliv. 2021 Feb;18(2):169-185. doi: 10.1080/17425247.2021.1823965. Epub 2020 Sep 29.
  31. Gbian DL,?Omri A. The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against?Pseudomonas aeruginosa. Pharmaceutics. 2021 Apr 18;13(4):577. doi: 10.3390/pharmaceutics13040577.
  32. Debnath SK, Srivastava R, Debnath M,?Omri A. Status of inhalable antimicrobial agents for lung infection: progress and prospects. Expert Rev Respir Med. 2021 Apr 17. doi: 10.1080/17476348.2021.1919514. Online ahead of print.
  33. Neha Desai, Momin M, Khan T, Gharat S, Ningthoujam RS,?Omri A. Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv. 2021 Apr 14:1-30. doi: 10.1080/17425247.2021.1912008. Online ahead of print.
  34. Jhaveri J, Raichura Z, Khan T, Momin M,?Omri A. Chitosan Nanoparticles-Insight into Properties, Functionalization and Applications in Drug Delivery and Theranostics. Molecules. 2021 Jan 7;26(2):272. doi: 10.3390/molecules26020272.
  35. Gbian DL,?Omri A. Current and novel therapeutic strategies for the management of cystic fibrosis. Expert Opin Drug Deliv. 2021 Jan 22:1-18. doi: 10.1080/17425247.2021.1874343. Online ahead of print.
  36. Debnath SK, Srivastava R, Omri A. Expert Opin Emerg Drugs. 2020 Sep;25(3):337-351. doi: 10.1080/14728214.2020.1810663. Epub 2020 Sep 8.
  37. Khan T, Mayuresh Patkar M, Momin M, Omri A. Expert Opin Drug Deliv. 2020 Jul;17(7):903-918. doi: 10.1080/17425247.2020.1762565. Epub 2020 May 26.
  38. Pervin MA, Jahan H, Akter R,?Omri A, Hossain Z. Appraisal of different levels of soybean meal in diets on growth, digestive enzyme activity, antioxidation, and gut histology of tilapia (Oreochromis niloticus). Fish Physiol Biochem. 2020 Aug;46(4):1397-1407. doi: 10.1007/s10695-020-00798-5. Epub 2020 Mar 28.
  39. Rana H, Dholakia M, Gohel M,?Omri A, Thakkar V, Gandhi T. Demonstration of advanced data mining tools for optimization of pellets employing modified extrusion-pelletization technique. Curr Drug Ther. 2020: 15: 1-16. doi: 10.2174/1574885515999201217155123.
  40. Kalubi K, Theriault G, Michael P,?Omri A. Low stringency tests revealed differential gene expression in red maple (Acer rubrum) treated with low doses of nickel. Plant Gene. 2020: 24: 100251-16. doi: 10.1016/j.plgene.2020.100251.
  41. Sankhe K, Khan T, Bhavsar C, Momin M,?Omri A. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB. Expert Opin Drug Deliv. 2019 Apr 22:1-14. doi: 10.1080/17425247.2019.1609937.
  42. Jorch SK, Surewaard BG, Hossain M, Peiseler M, Deppermann C, Deng J, Bogoslowski A, van der Wal F,?Omri A, Hickey MJ, Kubes P. Peritoneal GATA6+ macrophages function as a portal for?Staphylococcus aureus?dissemination. J Clin Invest. 2019 Nov 1;129(11):4643-4656.
  43. Jadhav M, Khan T, Bhavsar C, Momin M,?Omri A. Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs. Expert Opin Drug Deliv. 2019 Jul;16(7):687-699.
  44. Gupta S, Kesarla R,?Omri A. Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment. Expert Opin Drug Deliv. 2019 Mar;16(3):287-300. doi: 10.1080/17425247.2019.1583206.
  45. Hardik B. Rana, Mukesh C. Gohel, Mansi S. Dholakia, Tejal R. Gandhi,?Abdelwahab Omri, Vaishali T. Thakkar. Vulnerability of Hydro-Alcoholic Media on In Vitro Drug Release from Galantamine HBr Pellets Comprising of Compritol 888 ATO and Ethocel. Research J. Pharm. and Tech 2019; 12(2):791-798.